GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL

Category Primary study
ConferenceEHA2023 Hybrid Congress
Year 2023
This article has no abstract
Epistemonikos ID: 307072d4116ffb8db3037497f323fb793e42c2dc
First added on: Apr 25, 2026